Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Income (2020 - 2025)

Arcutis Biotherapeutics has reported Net Income over the past 6 years, most recently at $17.4 million for Q4 2025.

  • Quarterly results put Net Income at $17.4 million for Q4 2025, up 260.98% from a year ago — trailing twelve months through Dec 2025 was -$16.2 million (up 88.45% YoY), and the annual figure for FY2025 was -$16.2 million, up 88.45%.
  • Net Income for Q4 2025 was $17.4 million at Arcutis Biotherapeutics, up from $7.4 million in the prior quarter.
  • Over the last five years, Net Income for ARQT hit a ceiling of $17.4 million in Q4 2025 and a floor of -$107.7 million in Q3 2022.
  • Median Net Income over the past 5 years was -$48.5 million (2023), compared with a mean of -$46.8 million.
  • Biggest five-year swings in Net Income: tumbled 109.27% in 2021 and later soared 260.98% in 2025.
  • Arcutis Biotherapeutics' Net Income stood at -$71.3 million in 2021, then fell by 1.03% to -$72.0 million in 2022, then grew by 7.98% to -$66.3 million in 2023, then skyrocketed by 83.72% to -$10.8 million in 2024, then soared by 260.98% to $17.4 million in 2025.
  • The last three reported values for Net Income were $17.4 million (Q4 2025), $7.4 million (Q3 2025), and -$15.9 million (Q2 2025) per Business Quant data.